Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?

• Published in: Journal of clinical medicine Vol. 13; no. 2; p. 549
• Main Authors: Rahmé, Ramy, Braun, Thorsten
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.01.2024
• Subjects: AML; Apoptosis; Cancer; Cell cycle; Chemotherapy; Chemotherapy, Combination; Cytogenetics; Cytotoxicity; Diseases; DNA damage; Drug dosages; Enzyme inhibitors; Kinases; Leukemia; Medical prognosis; Metabolism; Methods; refractory; Relapse; relapsed; Remission (Medicine); Senescence; Stem cells; Transplantation; venetoclax; France; AML; relapsed; leukemia; refractory; venetoclax; chemotherapy
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm13020549

. Primary resistance of acute myeloid leukemia (AML) to the conventional 3 + 7 intensive chemotherapy and relapses after first-line chemotherapy are two highly challenging clinical scenarios. In these cases, when allogeneic stem cell transplantation is feasible, patients are usually retreated with other chemotherapeutic regimens, as transplantation is still considered, nowadays, the only curative option. . We discuss the mechanisms behind resistance to chemotherapy and offer a comprehensive review on current treatments of refractory/relapsed AML with a focus on novel approaches incorporating the BCL-2 inhibitor venetoclax. . Alas, complete remission rates after salvage chemotherapy remain relatively low, between 30 and 60% at best. More recently, the BCL-2 inhibitor venetoclax was combined either with hypomethylating agents or chemotherapy in refractory/relapsed patients. In particular, its combination with chemotherapy offered promising results by achieving higher rates of remission and bridging a substantial number of patients to transplantation. . Venetoclax-based approaches might become, in the near future, the new standard of care for refractory/relapsed AML.